These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27932799)

  • 21. B cells and their role in shaping the immune response in squamous cell carcinoma of the head and neck.
    Economopoulou P; Kotsantis I; Psyrri A
    Immunotherapy; 2021 Jun; 13(9):723-726. PubMed ID: 33910385
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunotherapy in the management of squamous cell carcinoma of the head and neck.
    Subramaniam SS; Paterson C; McCaul JA
    Br J Oral Maxillofac Surg; 2019 Dec; 57(10):957-966. PubMed ID: 31653434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editorial: Head and neck cancers: new perspectives in prevention and treatment.
    Guigay J
    Curr Opin Oncol; 2020 May; 32(3):177. PubMed ID: 32209824
    [No Abstract]   [Full Text] [Related]  

  • 24. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B; Young RJ; Rischin D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
    Bowles DW; McDermott JD; Jimeno A
    Future Oncol; 2014 May; 10(6):1065-80. PubMed ID: 24941990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Author's reply to "A novel seven-gene panel predicts the sensitivity and prognosis of head and neck squamous cell carcinoma treated with platinum-based radio(chemo)therapy".
    Wang L; Wang R; Fang J
    Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3599-3600. PubMed ID: 34255146
    [No Abstract]   [Full Text] [Related]  

  • 27. [Research progress in immunotherapy of head and neck squamous cell carcinoma].
    He CH; Li XM
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Jan; 57(1):82-88. PubMed ID: 35090219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The NKG2A immune checkpoint - a new direction in cancer immunotherapy.
    Creelan BC; Antonia SJ
    Nat Rev Clin Oncol; 2019 May; 16(5):277-278. PubMed ID: 30824813
    [No Abstract]   [Full Text] [Related]  

  • 29. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
    Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
    Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunotherapy for head and neck squamous cell carcinoma].
    Chen J; Chen M; Wu HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Feb; 52(2):143-147. PubMed ID: 28219181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Immune Suppression in Cancer.
    Cancer Discov; 2016 Dec; 6(12):OF9. PubMed ID: 27920143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pseudoprogression during Immunotherapy in Metastatic Head and Neck Squamous Cell Carcinoma.
    Bedmutha A; Kaushal A
    Radiol Imaging Cancer; 2022 May; 4(3):e220037. PubMed ID: 35549358
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
    Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
    Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges.
    Bruixola G; Remacha E; Jiménez-Pastor A; Dualde D; Viala A; Montón JV; Ibarrola-Villava M; Alberich-Bayarri Á; Cervantes A
    Cancer Treat Rev; 2021 Sep; 99():102263. PubMed ID: 34343892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma.
    Mao L; Zhao ZL; Yu GT; Wu L; Deng WW; Li YC; Liu JF; Bu LL; Liu B; Kulkarni AB; Zhang WF; Zhang L; Sun ZJ
    Int J Cancer; 2018 Mar; 142(5):999-1009. PubMed ID: 29047105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Schoppy DW; Sunwoo JB
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1033-43. PubMed ID: 26568546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for head and neck cancer patients: shifting the balance.
    Turksma AW; Braakhuis BJ; Bloemena E; Meijer CJ; Leemans CR; Hooijberg E
    Immunotherapy; 2013 Jan; 5(1):49-61. PubMed ID: 23256798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunomodulation as innovative therapy for head and neck tumors : Current developments].
    Schuler PJ; Doescher JC; Laban S; Hoffmann TK
    HNO; 2016 Jul; 64(7):470-8. PubMed ID: 26912050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.
    Younis RH; Han KL; Webb TJ
    J Immunol; 2016 Feb; 196(3):1419-29. PubMed ID: 26740106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting cancer associated fibroblasts - A TGF-β based immunotherapy for head and neck squamous cell carcinoma.
    Pazhani J; Jayaraman S; Veeraraghavan VP; Somasundaram DB; Raj AT; Patil S
    Oral Oncol; 2022 Jul; 130():105899. PubMed ID: 35561489
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.